Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.63 |
| ▸ | DPP4 | P27487 | 3/20 | 0.63 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 4/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PTPRC | P08575 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | S100A4 | P26447 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9812679 | 0.80 | ANPEP (0.62) | ANPEPDPP4CA12CA9CA1 | |
| SCHEMBL13171786 | 0.79 | ANPEP (0.71) | ANPEPDPP4NR1H2NR1H3CA12 | |
| SCHEMBL2820118 | 0.77 | DPP4 (0.78) | ANPEPDPP4NR1H2NR1H3 | |
| SCHEMBL29366407 | 0.77 | DPP4 (0.78) | ANPEPDPP4NR1H2NR1H3 | |
| SCHEMBL9812636 | 0.77 | ANPEP (0.69) | ANPEPDPP4NR1H2NR1H3 | |
| SCHEMBL2818285 | 0.77 | ANPEP (1.00) | ANPEPDPP4NR1H2NR1H3ALDH1A1 | |
| SCHEMBL173289 | 0.77 | ANPEP (1.00) | ANPEPDPP4NR1H2NR1H3 | |
| SCHEMBL9468420 | 0.77 | SCN2A (0.74) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL1468419 | 0.77 | CA12 (0.64) | CA12CA9CA1CA2ALDH1A1 | |
| SCHEMBL9807445 | 0.76 | CA12 (0.53) | ANPEPDPP4NR1H2NR1H3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100247659-A1 | PHENYLPHTHALIMIDE ANALOGS FOR TREATING DIABETIC MACULAR EDEMA | CHARLESSON, LLC (US) | 2010-09-30 | — | — | US | claimed |
| JP-10072346-A | — | — | None | — | — | JP | disclosed |
| US-20100247659-A1 | PHENYLPHTHALIMIDE ANALOGS FOR TREATING DIABETIC MACULAR EDEMA | CHARLESSON, LLC (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100247659-A1 | PHENYLPHTHALIMIDE ANALOGS FOR TREATING DIABETIC MACULAR EDEMA | CHARLESSON, LLC (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100247659-A1 | PHENYLPHTHALIMIDE ANALOGS FOR TREATING DIABETIC MACULAR EDEMA | CHARLESSON, LLC (US) | 2010-09-30 | — | — | US | disclosed |
| US-6515129-B1 | A pharmaceutical composition which comprises, a cyclic imide derivative represented by the general formula (I): present invention relates to an aminopeptidase N inhibitor or an angiogenesis inhibitor, modulates production of tumor necrosis | ISHIHARA SANGYO KAISHA LTD. (JP) | 2003-02-04 | — | — | US | disclosed |
| US-6429212-B1 | AMINOPEPTIDASE N INHIBITOR USED TO TREAT CANCER, TUMORS, AND RETINOPATHY; FEW SIDE EFFECTS; ANGIOGENESIS INHIBITOR | ISHIHARA SANGYO KAISHA LTD. (JP) | 2002-08-06 | — | — | US | disclosed |
| JP-H1072346-A | TUMOR NECROSIS FACTOR PRODUCTION-INHIBITING MEDICINE OR VASCULARIZATION-INHIBITING MEDICINE CONTAINING N-PHENYLPHTHALIMIDE DERIVATIVE | ISHIHARA SANGYO KAISHA LTD | 1998-03-17 | — | — | JP | disclosed |
| EP-0245989-B1 | FLUOROPHTHALIMIDES | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1991-07-10 | — | — | EP | disclosed |
| US-4839378-A | FOR CONTROLLING PLANT DISEASES | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1989-06-13 | — | — | US | disclosed |
| EP-0245989-A2 | Fluorophthalimides | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1987-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247659-A1 | PHENYLPHTHALIMIDE ANALOGS FOR TREATING DIABETIC MACULAR EDEMA | SLC2A8, VEGFA, SLC2A1 | ANPEP 363/4885DPP4 35/4885NR1H2 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.